Breakout Ventures Raises $114M for AI‑Biotech Startups

Breakout Ventures, a San Francisco‑based early‑stage investor, has closed Fund III at $114 million — its biggest pool of capital to date. The raise underscores a broader trend: venture dollars increasingly flow to founders who combine machine learning expertise with deep biological know‑how.

Founded by Lindy Fishburne out of a Thiel Foundation grant programme, Breakout has carved a niche betting on the convergence of AI and life sciences. The firm says that models, data and automation are now intrinsic parts of modern biology, and that companies bridging those disciplines will unlock faster research cycles and more scalable products.

With Fund III, Breakout plans to back startups across computational biology, wet lab automation, protein design, and AI‑driven drug discovery, among other areas. The fund size is modest compared with some mega‑funds, but it reflects Breakout’s focus on very early checks and hands‑on support — scouting teams that can move from concept to validation quickly.

Investors and limited partners have shown increasing appetite for thesis‑driven funds that target specific technical junctions, rather than broad sector plays. That helps explain why specialized firms like Breakout can raise meaningful sums: institutional and strategic backers want exposure to cutting‑edge companies that could redefine biotech R&D and therapeutics.

For founders, a specialist investor offers more than capital: expertise, lab access, and networks that matter when navigating regulated, expensive science. Breakout’s bet is that entrepreneurs who fluently speak both AI and biology will be the ones to build durable companies — and this new fund will give several of them the runway to try.